title: Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
abstract: Endemic and epidemic meningococcal disease constitutes a major public-health problem in African countries of the 'meningitis belt' where incidence rates of the disease are many-fold higher (up to 25 cases per 100,000 population) than those in industrialized countries, and epidemics of meningococcal disease occur with rates as high as 1,000 cases per 100,000 people. Using the precedent established during the licensing of conjugate vaccines against Haemophilus influenzae type b and serogroup C meningococci and components of currently-licensed meningococcal polysaccharide vaccines, new meningococcal conjugate vaccines will likely be licensed using immunological endpoints as surrogates for clinical protection. Post-licensure evaluation of vaccine effectiveness will, therefore, be of increased importance. One vaccine being developed is the serogroup A meningococcal (Men A) conjugate vaccine produced by the Meningitis Vaccine Project (MVP), a partnership between the World Health Organization and the Program for Applied Technology in Health. This vaccine will likely be the first meningococcal conjugate vaccine introduced on a large scale in Africa. This paper summarizes the general steps required for vaccine development, reviews the use of immunogenicity criteria as a licensing strategy for new meningococcal vaccines, and discusses plans for evaluating the impact of a meningococcal A conjugate vaccine in Africa. Impact of this vaccine will be measured during a vaccine-demonstration project that will primarily measure the effectiveness of vaccine. Other studies will include evaluations of safety, vaccine coverage, impact on carriage and herd immunity, and prevention-effectiveness studies.
authors.affiliation: Meningitis and Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. zzd7@cdc.gov
authors.forename: Montse
authors.initials: M
authors.lastname: Soriano-Gabarró
authors.forename: Nancy
authors.initials: N
authors.lastname: Rosenstein
authors.forename: F Marc
authors.initials: FM
authors.lastname: LaForce
mesh_terms: D000349:Africa; D003362:Cost-Benefit Analysis; D006801:Humans; D017589:Immunization Programs / Q000379:methods / Q000458:organization & administration* / Q000592:standards; D008585:Meningitis, Meningococcal / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology* / Q000627:therapeutic use; D012703:Serotyping; D016896:Treatment Outcome; D018074:Vaccines, Conjugate / Q000276:immunology / Q000627:therapeutic use
chemical_list: D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate